1
|
Raffals LE, Saha S, Bewtra M, Norris C, Dobes A, Heller C, O’Charoen S, Fehlmann T, Sweeney S, Weaver A, Bishu S, Cross R, Dassopoulos T, Fischer M, Yarur A, Hudesman D, Parakkal D, Duerr R, Caldera F, Korzenik J, Pekow J, Wells K, Bohm M, Perera L, Kaur M, Ciorba M, Snapper S, Scoville EA, Dalal S, Wong U, Lewis JD. The Development and Initial Findings of A Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD). Inflamm Bowel Dis 2021; 28:192-199. [PMID: 34436563 PMCID: PMC9013198 DOI: 10.1093/ibd/izab071] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/24/2021] [Indexed: 12/19/2022]
Abstract
BACKGROUND Clinical and molecular subcategories of inflammatory bowel disease (IBD) are needed to discover mechanisms of disease and predictors of response and disease relapse. We aimed to develop a study of a prospective adult research cohort with IBD (SPARC IBD) including longitudinal clinical and patient-reported data and biosamples. METHODS We established a cohort of adults with IBD from a geographically diverse sample of patients across the United States with standardized data and biosample collection methods and sample processing techniques. At enrollment and at time of lower endoscopy, patient-reported outcomes (PRO), clinical data, and endoscopy scoring indices are captured. Patient-reported outcomes are collected quarterly. The quality of clinical data entry after the first year of the study was assessed. RESULTS Through January 2020, 3029 patients were enrolled in SPARC, of whom 66.1% have Crohn's disease (CD), 32.2% have ulcerative colitis (UC), and 1.7% have IBD-unclassified. Among patients enrolled, 990 underwent colonoscopy. Remission rates were 63.9% in the CD group and 80.6% in the UC group. In the quality study of the cohort, there was 96% agreement on year of diagnosis and 97% agreement on IBD subtype. There was 91% overall agreement describing UC extent as left-sided vs extensive or pancolitis. The overall agreement for CD behavior was 83%. CONCLUSION The SPARC IBD is an ongoing large prospective cohort with longitudinal standardized collection of clinical data, biosamples, and PROs representing a unique resource aimed to drive discovery of clinical and molecular markers that will meet the needs of precision medicine in IBD.
Collapse
Affiliation(s)
- Laura E Raffals
- Address correspondence to: Laura E. Raffals, MD, MS, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA. E-mail:
| | - Sumona Saha
- University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
| | - Meenakshi Bewtra
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Cecile Norris
- Crohn’s & Colitis Foundation, New York, New York, USA
| | - Angela Dobes
- Crohn’s & Colitis Foundation, New York, New York, USA
| | - Caren Heller
- Crohn’s & Colitis Foundation, New York, New York, USA
| | | | - Tara Fehlmann
- Crohn’s & Colitis Foundation, New York, New York, USA
| | - Sara Sweeney
- Crohn’s & Colitis Foundation, New York, New York, USA
| | | | | | - Raymond Cross
- University of Maryland School of Medicine, Baltimore, Maryland, USA
| | | | | | - Andres Yarur
- Medical College of Wisconsin, Milwaukee, Wisconsin, USA
| | - David Hudesman
- New York University Langone Health, New York, New York, USA
| | - Deepak Parakkal
- Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA
| | - Richard Duerr
- University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Freddy Caldera
- University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
| | | | - Joel Pekow
- University of Chicago, Chicago, Illinois, USA
| | - Katerina Wells
- Baylor Scott and White Health and Baylor University Medical Center at Dallas, TX, USA
| | | | - Lilani Perera
- Advocate Aurora Healthcare, Milwaukee, Wisconsin, USA
| | | | - Matthew Ciorba
- Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA
| | - Scott Snapper
- Boston Children’s Hospital and Brigham and Women’s Hospital, Boston, Massachusetts, USA
| | | | | | - Uni Wong
- University of Maryland School of Medicine, Baltimore, Maryland, USA
| | - James D Lewis
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
| |
Collapse
|
2
|
Boucher G, Paradis A, Chabot-Roy G, Coderre L, Hillhouse EE, Bitton A, Des Rosiers C, Levings MK, Schumm LP, Lazarev M, Brant SR, Duerr R, McGovern D, Silverberg MS, Cho J, Lesage S, Rioux JD. Serum Analyte Profiles Associated With Crohn's Disease and Disease Location. Inflamm Bowel Dis 2021; 28:9-20. [PMID: 34106269 PMCID: PMC8730700 DOI: 10.1093/ibd/izab123] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/10/2020] [Indexed: 12/14/2022]
Abstract
BACKGROUND Crohn's disease (CD) can affect any segment of the digestive tract but is most often localized in the ileal, ileocolonic, and colorectal regions of the intestines. It is believed that the chronic inflammation in CD is a result of an imbalance between the epithelial barrier, the immune system, and the intestinal microbiota. The aim of the study was to identify circulating markers associated with CD and/or disease location in CD patients. METHODS We tested 49 cytokines, chemokines, and growth factors in serum samples from 300 patients with CD and 300 controls. After quality control, analyte levels were tested for association with CD and disease location. RESULTS We identified 13 analytes that were higher in CD patients relative to healthy controls and that remained significant after conservative Bonferroni correction (P < 0.0015). In particular, CXCL9, CXCL1, and interleukin IL-6 had the greatest effect and were highly significant (P < 5 × 10-7). We also identified 9 analytes that were associated with disease location, with VEGF, IL-12p70, and IL-6 being elevated in patients with colorectal disease (P < 3 × 10-4). CONCLUSIONS Multiple serum analytes are elevated in CD. These implicate the involvement of multiple cell types from the immune, epithelial, and endothelial systems, suggesting that circulating analytes reflect the inflammatory processes that are ongoing within the gut. Moreover, the identification of distinct profiles according to disease location supports the existence of a biological difference between ileal and colonic CD, consistent with previous genetic and clinical observations.
Collapse
Affiliation(s)
| | - Alexandre Paradis
- Maisonneuve-Rosemont Hospital Research Center, Montréal, Québec, Canada
| | | | - Lise Coderre
- Maisonneuve-Rosemont Hospital Research Center, Montréal, Québec, Canada
| | - Erin E Hillhouse
- Maisonneuve-Rosemont Hospital Research Center, Montréal, Québec, Canada
| | - Alain Bitton
- Division of Gastroenterology, McGill University, Montreal, Québec, Canada
| | - Christine Des Rosiers
- Montreal Heart Institute, Montréal, Québec, Canada,Département de Nutrition, Université de Montréal, Montréal, Québec, Canada
| | - Megan K Levings
- BC Children’s Hospital Research Institute, Vancouver, British Columbia, Canada
| | - L Philip Schumm
- Department of Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| | - Mark Lazarev
- The Harvey M. and Lyn P. Meyerhoff Inflammatory Bowel Disease Center, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Steve R Brant
- The Harvey M. and Lyn P. Meyerhoff Inflammatory Bowel Disease Center, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA,Division of Gastroenterology and Hepatology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, and Department of Genetics and the Human Genetics Institute of New Jersey, Rutgers University, New Brunswick and Piscataway, New Jersey, USA
| | - Richard Duerr
- Department of Medicine, University of Pittsburgh, Pennsylvania, USA
| | - Dermot McGovern
- F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Mark S Silverberg
- Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Mount Sinai Hospital Inflammatory Bowel Disease Centre, Toronto, Ontario, USA
| | - Judy Cho
- Icahn School of Medicine, Mount Sinai, New York, New York, USA
| | - Sylvie Lesage
- Maisonneuve-Rosemont Hospital Research Center, Montréal, Québec, Canada,Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, Québec, Canada
| | - John D Rioux
- Montreal Heart Institute, Montréal, Québec, Canada,Département de Médicine, Université de Montréal, Montréal, Québec, Canada,Address for correspondence: John D. Rioux, Montreal Heart Institute Research Centre, 5000 Rue Bélanger, S-6201, Montreal, Quebec, H1T 1C8, Canada. E-mail:
| | | | | |
Collapse
|
3
|
|
4
|
Adamik J, Henkel M, Ray A, Auron PE, Duerr R, Barrie A. The IL17A and IL17F loci have divergent histone modifications and are differentially regulated by prostaglandin E2 in Th17 cells. Cytokine 2013; 64:404-12. [PMID: 23800789 DOI: 10.1016/j.cyto.2013.05.010] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2012] [Revised: 05/06/2013] [Accepted: 05/17/2013] [Indexed: 12/20/2022]
Abstract
Prostaglandin E2 (PGE2), IL-23 and IL-1β are implicated in inflammatory bowel disease susceptibility, likely in part by modulating IL-17 producing CD4(+) T helper (Th17) cells. To better understand how these three mediators affect Th17 cell memory responses, we characterized the gene expression profiles of activated human peripheral CD4(+) effector memory T cells and sorted Th17 memory cells from healthy donors concurrent with IL17A mRNA induction mediated by PGE2 and/or IL-23 plus IL-1β. We discovered that PGE2 and IL-23 plus IL-1β differentially regulate Th17 cytokine expression and synergize to induce IL-17A, but not IL-17F. IL-23 plus IL-1β preferentially induce IL-17F expression. The addition of PGE2 to IL-23 plus IL-1β only enhances IL-17A expression as mediated by the PGE2 EP4 receptor, and promotes a switch from an IL-17F to an IL-17A predominant immune response. The human Th17 HuT-102 cell line was also found to constitutively express IL-17A, but not IL-17F. We went on to show that the IL17A and IL17F loci have divergent epigenetic architectures in unstimulated HuT-102 and primary Th17 cells and are poised for preferential expression of IL17A. We conclude that the chromatin for IL17A and IL17F are distinctly regulated, which may play an important role in mucosal health and disease.
Collapse
Affiliation(s)
- Juraj Adamik
- Department of Biological Sciences, Duquesne University, Pittsburgh, PA 15282, USA
| | | | | | | | | | | |
Collapse
|
5
|
Barrie A, Khare A, Henkel M, Zhang Y, Barmada MM, Duerr R, Ray A. Prostaglandin E2 and IL-23 plus IL-1β differentially regulate the Th1/Th17 immune response of human CD161(+) CD4(+) memory T cells. Clin Transl Sci 2011; 4:268-73. [PMID: 21884514 DOI: 10.1111/j.1752-8062.2011.00300.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Prostaglandin E2 (PGE2), interleukin (IL)-23, and IL-1beta (β) propagate inflammatory bowel disease (IBD) by enhancing the development and function of IL-17 producing CD4(+) T helper (Th17) cells. CD4(+) T cells that express the C-type lectin-like receptor CD161 have been proposed to be the physiologic pool of circulating Th17 cells implicated in IBD. We sought to understand how PGE2, alone and in combination with IL-23 and IL-1β, modulate human peripheral CD161(+) CD4(+) memory T cells. We found that CD161(+) cells comprise a significant proportion of human peripheral CD4(+) memory T cells. PGE2 and IL-23 plus IL-1β synergistically induced early IL-17A secretion from CD161(+) CD4(+) memory T cells and the selective enrichment of IL-17A(+) CD161(+) CD4(+) memory T cells in culture. Conversely, IL-23 plus IL-1β partially opposed the PGE2-mediated repression of early interferon gamma (IFN-γ) secretion from CD161(+) cells, as well as the PGE2-mediated depletion of IFN-γ(+) CD161(+) cells. Our results suggest that PGE2 and IL-23 plus IL-1β induce the Th17 immune response preferentially in CD161(+) CD4(+) memory T cells, while divergently regulating their ability to express IFN-γ. We hypothesize that Th17-mediated chronic inflammation in IBD depends on the net response of CD161(+) CD4(+) memory T cells to both PGE2 and IL-23 plus IL-1β.
Collapse
Affiliation(s)
- Arthur Barrie
- Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
| | | | | | | | | | | | | |
Collapse
|
6
|
Bhat M, Nguyen GC, Pare P, Lahaie R, Deslandres C, Bernard EJ, Aumais G, Jobin G, Wild G, Cohen A, Langelier D, Brant S, Dassopoulos T, McGovern D, Torres E, Duerr R, Regueiro M, Silverberg MS, Steinhart H, Griffiths AM, Elkadri A, Cho J, Proctor D, Goyette P, Rioux J, Bitton A. Phenotypic and genotypic characteristics of inflammatory bowel disease in French Canadians: comparison with a large North American repository. Am J Gastroenterol 2009; 104:2233-40. [PMID: 19513023 PMCID: PMC2742627 DOI: 10.1038/ajg.2009.267] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
OBJECTIVES Phenotype characteristics of inflammatory bowel disease (IBD) may differ significantly among ethnic subpopulations. The aim of this study was to characterize the IBD phenotype in French Canadians, the most prominent founder population in North America. METHODS Using well-characterized phenotype data in the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-IBD Genetics Consortium repository on patients with IBD, we compared phenotypic characteristics of 202 French Canadians with those of 1,287 other Caucasian patients. These included diagnosis, anatomical location, disease behavior, extraintestinal manifestations, surgical history, and family history of IBD. RESULTS French-Canadian patients with Crohn's disease (CD) were less likely to have stricturing disease (11 vs. 21%, P=0.005; odds ratio (OR): 0.45, 95% confidence interval (95% CI): 0.24-0.85). Using a stringent definition of ethnicity (three out of four grandparents being French Canadians, as opposed to self-report, n=148), French Canadians had a tendency toward developing fistulizing CD (37 vs. 28%, P=0.07), and there was an increased prevalence of sacroiliitis among those with IBD (4 vs. 2%, P=0.045). Among French Canadians, the numbers of current smokers in CD (40 vs. 25%, P=0.006) and former smokers in ulcerative colitis (UC) (35 vs. 20%, P=0.03) were significantly higher. The prevalence of one of the three main variants of nucleotide-binding oligomerization domain containing 2 (NOD2) single-nucleotide polymorphisms (SNPs) among French-Canadian CD patients was 43.2%. The 3020insC SNP correlated with small bowel disease in French Canadians (25 [corrected] vs. 0%, P=0.006). CONCLUSIONS French Canadians show an IBD phenotype profile distinct from other Caucasian IBD populations, with an accentuated association between smoking status and IBD. This unique profile may have implications regarding the need for a different approach to the management of IBD in this population.
Collapse
Affiliation(s)
- Mamatha Bhat
- Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada
| | - Geoffrey C. Nguyen
- Department of Medicine, Mount Sinai Hospital Inflammatory Bowel Disease Centre, University of Toronto, Toronto, Canada
| | | | - Raymond Lahaie
- Hôpital St. Luc, Centre Hospitalier, Université de Montréal, Quebec, Canada
| | | | | | - Guy Aumais
- Hôpital Maisonneuve Rosemont, Montreal, Quebec, Canada
| | - Gilles Jobin
- Hôpital Maisonneuve Rosemont, Montreal, Quebec, Canada
| | - Gary Wild
- Montreal General Hospital, McGill University, Quebec, Canada
| | - Albert Cohen
- Jewish General Hospital, Montreal, Quebec, Canada
| | - Diane Langelier
- Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Quebec, Canada
| | - Steven Brant
- Harvey M. and Lyn P. Meyerhoff Inflammatory Bowel Disease Center, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Themistocles Dassopoulos
- Harvey M. and Lyn P. Meyerhoff Inflammatory Bowel Disease Center, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Dermot McGovern
- Division of Medical Genetics and Inflammatory Bowel Disease Center, Cedar-Sinai Medical Center, Los Angeles, California
| | - Esther Torres
- Department of Medicine, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, Puerto Rico
| | - Richard Duerr
- Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
| | - Miguel Regueiro
- Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
| | - Mark S Silverberg
- Department of Medicine, Mount Sinai Hospital Inflammatory Bowel Disease Centre, University of Toronto, Toronto, Canada
| | - Hillary Steinhart
- Department of Medicine, Mount Sinai Hospital Inflammatory Bowel Disease Centre, University of Toronto, Toronto, Canada
| | - Anne M. Griffiths
- Department of Medicine, Mount Sinai Hospital Inflammatory Bowel Disease Centre, University of Toronto, Toronto, Canada
| | - Abdul Elkadri
- Department of Medicine, Mount Sinai Hospital Inflammatory Bowel Disease Centre, University of Toronto, Toronto, Canada
| | - Judy Cho
- Department of Medicine, Section of Digestive Diseases, Yale University, New Haven, Connecticut
| | - Deborah Proctor
- Department of Medicine, Section of Digestive Diseases, Yale University, New Haven, Connecticut
| | - Philippe Goyette
- The Montréal Heart Institute and the Université de Montréal, Quebec, Canada
| | - John Rioux
- The Montréal Heart Institute and the Université de Montréal, Quebec, Canada
| | - Alain Bitton
- Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada
| |
Collapse
|
7
|
Chaudhry M, Chaudhry F, Eisenberg M, Nguyen H, Duerr R, Del Core M, Fourchy D, Huynh T, Lader E, Rogers F, Okrainec K, Wou K, Pilote L. Smokers are referred for coronary artery bypass graft surgery at a younger age than nonsmokers: results from The ROSETTA-CABG Registry. Cardiovascular Revascularization Medicine 2008. [DOI: 10.1016/j.carrev.2008.03.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
8
|
Rioux J, Xavier R, Taylor K, Goyette P, Silverberg M, Huett A, Green T, Kuballa P, Barmada M, Datta L, Shugart YY, Jean Bernard E, Mei L, Nicolae D, Steinhart H, Rotter J, Cho J, Daly M, Regueiro M, Schumm P, Duerr R, Brant S. Whole Genome Association Identifies Novel Susceptibility Genes for Crohn's Disease and Implicates a Crucial Role for Autophagy. Clin Immunol 2007. [DOI: 10.1016/j.clim.2007.03.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
9
|
|
10
|
Gulland FMD, Haulena M, Fauquier D, Langlois G, Lander ME, Zabka T, Duerr R. Domoic acid toxicity in Californian sea lions (Zalophus californianus): clinical signs, treatment and survival. Vet Rec 2002; 150:475-80. [PMID: 11995679 DOI: 10.1136/vr.150.15.475] [Citation(s) in RCA: 154] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Eighty-one Californian sea lions (Zalophus californianus) with signs of domoic acid toxicity stranded along the coast of California in 1998 when there were blooms of the domoic acid-producing alga Pseudonitzschia australis off-shore. In 2000, a further 184 sea lions stranded with similar clinical signs, but the strandings occurred both during detectable algal blooms and after the blooms had subsided. The clinical signs in these 265 Californian sea lions included seizures, ataxia, head weaving, decreased responsiveness to stimuli and scratching behaviour. Affected animals had high haematocrits, and eosinophil counts, and high activities of serum creatine kinase. They were treated supportively by using fluid therapy, diazepam, lorazepam and phenobarbitone. Fifty-five of the 81 sea lions (68 per cent) affected in 1998 and 81 of the 184 (44 per cent) affected in 2000 died despite the treatment. Three of the 23 sea lions which survived in 1998 were tracked with satellite and radiotransmitters; they travelled as far south as San Miguel Island, California, and survived for at least three months. Eleven of the 129 animals which were released stranded within four months of being released.
Collapse
Affiliation(s)
- F M D Gulland
- The Marine Mammal Center, Fort Cronkhite, Sausalito, CA 94965, USA
| | | | | | | | | | | | | |
Collapse
|
11
|
Abenhaim HA, Eisenberg MJ, Schechter D, Lefkovits J, Goudreau E, Deligonul U, Mak K, Duerr R, Del Core M, Huynh T, Smilovitch M, Sedlis S, Brown DL, Brieger D. Comparison of six-month outcomes of percutaneous transluminal coronary angioplasty in patients > or =75 with those <75 years of age (the ROSETTA registry). Am J Cardiol 2001; 87:1392-5. [PMID: 11397361 DOI: 10.1016/s0002-9149(01)01560-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
- H A Abenhaim
- Faculty of Medicine, McGill University and Jewish General Hospital, Montreal, Quebec, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Eisenberg MJ, Schechter D, Lefkovits J, Goudreau E, Deligonul U, Mak KH, Del Core M, Duerr R, Garzon PM, Huynh T, Smilovitch M, Sedlis S, Brown DL, Brieger D, Pilote L. Use of routine functional testing after percutaneous transluminal coronary angioplasty: results from the ROSETTA Registry. Am Heart J 2001; 141:837-46. [PMID: 11320375 DOI: 10.1067/mhj.2001.114373] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
BACKGROUND The American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for exercise testing suggest that only selected groups of high-risk patients should undergo routine functional testing after percutaneous transluminal coronary angioplasty (PTCA) for the detection of restenosis. OBJECTIVES Our purpose was (1) to document the patterns of use of post-PTCA functional testing and (2) to determine whether the choice of functional testing strategy is related to clinical characteristics of patients or whether physicians use a similar strategy for all their patients. METHODS The Routine Versus Selective Exercise Treadmill Testing After Angioplasty (ROSETTA) Registry is a prospective study examining the use of functional testing among 788 patients at 13 centers in 5 countries. RESULTS During the 6-month period after a successful PTCA, 49% of patients underwent functional testing (range among centers 10%-81%). Among patients who underwent functional testing, 39% had a clinical indication and 61% had functional testing as a routine follow-up. The first functional test was performed a median of 7 weeks after PTCA, with 13% of patients having second tests at a median of 14 weeks and 4% having additional tests at a median of 20 weeks. Univariate and multivariate analyses demonstrated that the chief determinant of the use of routine functional testing was clinical center. Aside from age (P <.0001), no baseline clinical or procedural characteristics were consistently associated with the use of routine functional testing after PTCA. CONCLUSIONS Physicians do not appear to be adhering to the ACC/AHA guidelines for exercise testing regarding the routine use of post-PTCA functional testing. None of the clinical characteristics identified by the ACC/AHA guidelines were associated with the routine use of post-PTCA functional testing, and the primary determinant of functional testing was the location of the center at which the patient had the PTCA.
Collapse
|
13
|
Affiliation(s)
- F Shanahan
- Department of Medicine, University of California, Los Angeles
| | | | | | | |
Collapse
|
14
|
Shanahan F, Targan S, Anton P, Duerr R. Colonoscopy during an attack of severe ulcerative colitis. Am J Gastroenterol 1991; 86:1278. [PMID: 1882815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|